Therapeutics: Peroxisome proliferation activated receptor γ (PPARγ)

Endocrine/metabolic disease

INDICATION: Obesity

Mouse studies suggest nanoparticles loaded with the generic PPARγ activator rosiglitazone and targeted to adipose

Read the full 172 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE